Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · Real-Time Price · USD

1.210

-0.040 (-3.20%)

At close: May 30, 2025, 4:00 PM

1.250

+0.040 (3.31%)

After-hours: May 30, 2025, 4:31 PM EDT

Pyxis Oncology Employees

Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.

Employees

44

Change (1Y)

-6

Growth (1Y)

-12.00%

Revenue / Employee

n/a

Profits / Employee

-$2,164,386

Market Cap

74.96M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	44	-6	-12.00%
Dec 31, 2023	50	-25	-33.33%
Dec 31, 2022	75	19	33.93%
Dec 31, 2021	56	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

PYXS News

15 days ago - Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
16 days ago - Pyxis Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
5 weeks ago - Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - GlobeNewsWire
2 months ago - Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewsWire
2 months ago - Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - GlobeNewsWire
2 months ago - Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
3 months ago - Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
3 months ago - Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - GlobeNewsWire